OFFICIAL-SOURCE RECALL · UNITED KINGDOM
National Patient Safety Alert: ResMed Astral 100 and 150 Recall: s involved in stopping treatment Affected
Use the identifiers printed on your item to determine whether this recall may affect the product you own.
CHECK THE ITEM YOU OWN
Is your product affected?
- Brand
- See official notice
- Product
- National Patient Safety Alert: ResMed Astral 100 and 150 Ventilators: Potential for Patient Harm due to Unexpected Interruption of Ventilation Therapy (NatPSA/2026/004/MHRA)
- Manufacturer
- See official notice
- Serial number / range
- numbers
The barcode may identify the product type, while the recall may apply only to certain lots, dates or variants. Check all identifiers listed in the official recall.
Why this product was recalled
s involved in stopping treatment Affected devices Key clinical considerations Stakeholder engagement Download document Date of Issue: 17 August 2026 Reference No: NatPSA/2026/004/MHRA This alert is for action by: all Hospital Trusts, Health Boards and independent healthcare providers delivering NHS, community, home ventilation and private healthcare services. This is a safety critical and complex National Patient Safety Alert. Implementation should be coordinated by an executive leader (or equivalent role in organisations without executive boards). Explanation of identified safety issue ResMed has issued a Field Safety Notice (FSN) regarding Astral 100 and 150 ventilators and associated Printed Circuit Board Assembly (PCBA) spare parts manufactured prior to October 2024. An internal supercapacitor may leak electrolyte, causing damage to specific circuitry of the PCBA and unexpected interruption of ventilation therapy. If the issue occurs while the ventilator is delivering therapy, ventilation therapy stops immediately; a high priority audible alarm activates, and the user interface may display therapy alarms and a Safety System Fault red screen. If the issue occurs while the devic
Hazard
s involved in stopping treatment Affected devices Key clinical considerations Stakeholder engagement Download document Date of Issue: 17 August 2026 Reference No: NatPSA/2026/004/MHRA This alert is for action by: all Hospital Trusts, Health Boards and independent healthcare providers delivering NHS, community, home ventilation and private healthcare services. This is a safety critical and complex National Patient Safety Alert. Implementation should be coordinated by an executive leader (or equivalent role in organisations without executive boards). Explanation of identified safety issue ResMed has issued a Field Safety Notice (FSN) regarding Astral 100 and 150 ventilators and associated Printed Circuit Board Assembly (PCBA) spare parts manufactured prior to October 2024. An internal supercapacitor may leak electrolyte, causing damage to specific circuitry of the PCBA and unexpected interruption of ventilation therapy. If the issue occurs while the ventilator is delivering therapy, ventilation therapy stops immediately; a high priority audible alarm activates, and the user interface may display therapy alarms and a Safety System Fault red screen. If the issue occurs while the devic
Official recall notice
National Patient Safety Alert: ResMed Astral 100 and 150 Ventilators: Potential for Patient Harm due to Unexpected Interruption of Ventilation Therapy (NatPSA/2026/004/MHRA)
Agency: Medicines and Healthcare products Regulatory Agency
Official publication date: August 17, 2026
Read the official UK_MHRA recall notice →Scan products you own
Scan products you own once and let RecallGuard monitor future official recalls.
Scan & Monitor Products